| CAT # | Izina ryibicuruzwa | Ibisobanuro |
| CPD100587 | Phlorizin | Phlorizin, nanone yitwa phloridzin, ni glucoside ya phloretine, dihydrochalcone, umuryango wa flavonoide ya gare, na yo ikaba ari itsinda rito mu nzira itandukanye ya fenilpropanoide synthesis. Phlorizin ni inhibitor irwanya SGLT1 na SGLT2 kuko irushanwa na D-glucose kugirango ihuze nuwitwaye; ibi bigabanya ubwikorezi bwa glucose yimpyiko, bigabanya urugero rwa glucose mumaraso. Phlorizin yizwe nk'ubuvuzi bushobora kuvura indwara ya diyabete yo mu bwoko bwa 2, ariko kuva ubwo yasimbuwe n’ibindi byinshi byatoranijwe kandi bitanga icyizere, nka canagliflozin na dapagliflozin. |
| CPD0045 | Ipragliflozin | Ipragliflozin, izwi kandi ku izina rya ASP1941, ni inzitizi ikomeye kandi ihitamo SGLT2 inhibitori yo kuvura diyabete yo mu bwoko bwa 2. Ubuvuzi bwa Ipragliflozin bwateje imbere indwara ya glycemic iyo yongewe ku buvuzi bwa metformin kandi birashobora kuba bifitanye isano no kugabanya ibiro no kugabanya umuvuduko wamaraso ugereranije na placebo. Ipragliflozin ntabwo itera hyperglycemia gusa ahubwo inatera diyabete / umubyibuho ukabije ujyanye no guhindagurika kwa metabolike idasanzwe mu mbeba ya diyabete yo mu bwoko bwa 2. Byemejwe gukoreshwa mu Buyapani mu 2014 |
| CPD100585 | Tofogliflozin | Tofogliflozin, izwi kandi ku izina rya CSG 452, ni inzitizi ikomeye kandi ihitamo SGLT2 ikumira mu gihe cyo kuvura indwara ya diyabete. Tofogliflozin itezimbere glycemic kandi igabanya uburemere bwumubiri kubarwayi barwaye diyabete yo mu bwoko bwa 2. Tofogliflozin dose-iterwa na glucose yinjira muri selile. Indwara ya glucose nyinshi (30? MM) kuri 4 na 24? H yiyongereye cyane kubyara okiside itera imbaraga mu ngirabuzimafatizo, zahagaritswe no kuvura tofogliflozine cyangwa antioxydeant N-acetylcysteine (NAC). |
| CPD100583 | Empagliflozin | Empagliflozin, izwi kandi ku izina rya BI10773 (izina ry'ubucuruzi Jardiance), ni imiti yemerewe kuvura diyabete yo mu bwoko bwa 2 ku bantu bakuru mu 2014. Yakozwe na Boehringer Ingelheim na Eli Lilly na Sosiyete. Empagliflozin ni inzitizi ya sodium glucose co-transport-2 (SGLT-2), kandi itera isukari mu maraso kwinjizwa nimpyiko ikavaho mu nkari. Empagliflozin ni inhibitori ya sodium glucose co-transport-2 (SGLT-2), iboneka hafi ya tubules yegeranye yibice bya nephronique mu mpyiko. SGLT-2 ihwanye na 90 ku ijana bya glucose reabsorption mumaraso. |
| CPD100582 | Canagliflozin | Canagliflozin (INN, izina ry'ubucuruzi Invokana) ni umuti wo kuvura diyabete yo mu bwoko bwa 2. Yakozwe na Mitsubishi Tanabe Pharma kandi igurishwa ku ruhushya na Janssen, ishami rya Johnson & Johnson. Canagliflozin ni inzitizi ya subtype 2 ya sodium-glucose itwara poroteyine (SGLT2), ishinzwe byibura 90% bya glucose reabsorption mu mpyiko. Guhagarika uyu mutwara bitera glucose yamaraso kurandurwa binyuze mu nkari. Muri Werurwe 2013, canagliflozin yabaye inhibitor ya mbere ya SGLT2 yemerewe muri Amerika |
| CPD0003 | Dapagliflozin | Dapagliflozin, izwi kandi ku izina rya BMS-512148, ni imiti ikoreshwa mu kuvura diyabete yo mu bwoko bwa 2 yemejwe mu 2012 na FDA. Dapagliflozin ibuza subtype ya 2 ya poroteyine yo gutwara sodium-glucose (SGLT2) ishinzwe byibura 90% bya glucose reabsorption mu mpyiko. Guhagarika ubu buryo bwo gutwara ibintu bituma glucose yamaraso ikurwaho binyuze mu nkari. Mu bigeragezo byo kwa muganga, dapagliflozin yagabanije HbA1c kuri 0,6 ugereranije n’amanota ya pointbo iyo yongewe kuri metformin |
